Comparative Pharmacology
Head-to-head clinical analysis: PENAPAR VK versus PROSTAPHLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENAPAR VK versus PROSTAPHLIN.
PENAPAR-VK vs PROSTAPHLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Prostaphlin (oxacillin) is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1 and PBP3, leading to inhibition of transpeptidation and cell lysis. It is resistant to staphylococcal beta-lactamases.
250-500 mg orally every 6 hours; maximum 2 g/day.
250-500 mg IM or IV every 4-6 hours for moderate to severe infections. For oral use: 250-500 mg every 6 hours on empty stomach.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour in normal renal function; prolonged to 7–10 hours in severe renal impairment (anuria). Requires dose adjustment in renal failure.
0.4-0.8 hours in adults with normal renal function; prolonged in renal impairment (up to 4-6 hours in anuria).
Primarily renal excretion (tubular secretion) of unchanged drug (~90%); minor biliary/fecal elimination (<10%).
Primarily renal (70-80% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic